Sales
$5M-$50M
EBITDA
Positive
Industry
Healthcare
Geography
US, Europe, Mid East, APAC
Investment Criteria
Sellside Group represents HRV Pharma, seeking asset-light businesses downstream of the API layer with established IP and market access to scale a global commercialization network.
Investment Criteria:
Revenue: $5M – $50M | EBITDA Positive
Founder-owned firms or strategic dossier/product-line carve-outs.
Asset-light operating models with no manufacturing/hard assets.
Core Assets (Human and Animal Health): Distribution Platforms, Regulatory Agents with Product Portfolios (Human / Animal Products), Dossiers and/or carve outs (Human / Animal). Drug Master Files (DMFs) / Veterinary Master Files (VMF).
Industry Criteria: (Human and Veterinary)
Corporate Carve-outs: Non-core product portfolios or dossiers from larger pharma. (to include customer access post transaction)
Dossier / V/DMF-Driven B2B Platforms: IP-led businesses supplying global partners.
Commercial & Distribution Platforms: Low-capital businesses protected by significant regulatory barriers.
In-licensing & Lifecycle Management: Platforms focused on product registration/acquisition.
Specialty Pharma Niches: Focused portfolios (e.g., orphan drugs) under asset-light models.
Buyer Highlights
Legacy Preservation: Offers a culture that respects the entrepreneurial spirit, existing management teams, and the long-term heritage of the company.
Partnership Approach: Structured to provide meaningful options to business owners through both cash and/or equity, fostering true alignment
IP Creation Capability: Proven capability to generate IP enabling first-to-file and first-to-market for its customers – 18 DMFs in 24 months. Now enhancing by deploying in-silico development or products
Operational Excellence: Tracking a revenue per employee of over USD 1 million; ROCE of over 50% and 8-year revenue CAGR of 76%
Category Defining Vision: Orchestrating ecosystems to create Long-term value through the expansion of regulatory footprints, global distribution rights and speed of execution
Experienced Leadership Backgrounds: Leadership team carries a combination of specialized talent across Pharma, Banking, Energy and Technology with experience of acquisitions, equity expansion and listing in public markets
Managing Director
Pablo DeMora
Managing Director Email
Senior Associate
Cameron Burress